Skip to main content
TNGX logo

TNGX · Tango Therapeutics, Inc.

Track TNGX — free
$21.96 -0.76 (-3.32%)
Market Cap
$3.85B
Shares
169.46M
Volume · Nov 20 802.34K Avg daily vol (3M) 3.41M

Price & Indicators

 

Key stats

Close
$22.71
Thu 19 Nov
Open
$22.15
Thu 19 Nov
Average volume, 30 days
3.9M
shares a session
Short interest
48.2M
28.5% of shares · 9.7 days to cover
Day range
$22.09$23.66
Open $22.15 Close $22.71
52-week closing range
$8.29$32.90
Close $22.71 31.0% under the high
Short volume, last session
55%
Latest filing
10-Q · Nov 9
Price history
Sep 2020 to Nov 2026

Latest documents

2026
Nov 10
Investor event
Frontline pancreatic study planned

Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.

3 source passages
I'm with Tango Therapeutics this morning. At ESMO we disclosed our plan to start a frontline study. A phase three study in front-line pancreatic cancer in the first half of next year. The study we suggested to FDA was a one-to-one randomized clinical trial of 240 patients in each arm. We are proposing, and FDA was fully in line with this, response rate and progression-free survival as dual primary endpoints. Open the document at this passage
Nov 9
Current report 8-K
82% ORR supports planned Phase 3 daraxonrasib combination trial

Tango Therapeutics reported 82% ORR and 88% PFS for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3 in first half of 2027, and held $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026.

Financial results
5 source passages
Data demonstrated that vopimetostat in combination with daraxonrasib achieved an 82% objective response rate (ORR) and 88% nine-month progression-free survival (PFS) rate in efficacy evaluable patients with second and third line pancreatic ductal adenocarcinoma (PDAC), and median PFS was not yet reached. Based upon the encouraging Phase 1/2 data and discussions with the US Food and Drug Administration (FDA), Tango intends to initiate a pivotal Phase 3 study of the combination of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer. The Company plans to initiate the study in the first half of 2027. As of September 30, 2026, the Company held $977.5 million in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan. Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Combination shows 82% ORR, plans registrational trial

Tango Therapeutics reported an 82% ORR for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with MTAP-deleted/RAS-mutant PDAC and plans a global, randomized registrational trial in first-line PDAC in the first half of 2027.

Revenue $0 Net loss $68.39M Diluted EPS -$0.39
Read from the MD&A section
4 source passages
Tango was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. In efficacy-evaluable PDAC patients with MTAP-deleted, RAS-mutant PDAC, we observed an ORR of 82% (18 of 22 patients, with 11 of 18 cPRs and 7 unconfirmed partial responses), an 88% 9-month PDF rate and a 100% DCR. Following recent interactions with the FDA, we plan to initiate a global, randomized registrational trial evaluating the combination of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted PDAC. We anticipate initiating this study in the first half of 2027. Open the document at this passage
Oct 23
Investor event
Combination shows 82% response rate; Phase III planned for 2027

Tango's updated data for vopametistat with Diracxon RASIB in pancreatic cancer show an objective response rate of 82% among 22 patients with metastatic pancreatic cancer and a nine-month progression-free survival rate of 88%. The company plans to start a Phase III study in first-line MTAP-deleted pancreatic cancer, anticipated to enroll 484 patients, in the first half of 2027. It also plans to start a study in MTAP wild-type pancreatic cancer in the first half of 2027.

5 source passages
among the 22 patients with metastatic pancreatic cancer, the objective response rate was 82% The nine-month landmark PFS rate is 88% In the first half of 2027, we intend to launch a pivotal study in patients with MTAP-deleted pancreatic cancer in the frontline setting. The study is anticipated to enroll 484 patients. In the first half of 2027, we intend to evaluate VOCA metastat in combination with a PAN-RAS inhibitor in approximately 25 to 30 patients with mTAP wild-type pancreatic cancer Open the document at this passage
Oct 23
Current report 8-K
Vopimetostat Combination Shows 82% Response Rate in Pancreatic Cancer

Tango Therapeutics reported an 82% objective response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with second line or third line MTAP-deleted/RAS-mutant pancreatic cancer. It plans to start a randomized registrational trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. It also intends to reduce its workforce by approximately 14% as part of a strategic reprioritization.

Regulation FD disclosure, Other events Read from the first part of this long document
3 source passages
updated data from the ongoing Phase 1/2 study demonstrated an 82% objective response rate (“ORR”), median progression-free survival (“PFS”) not yet reached, and a 9-month PFS rate of 88% in 22 patients with second line or third line MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable. The Company anticipates initiating this study in the first half of 2027. the Company intends to reduce its overall workforce by approximately 14%, with the majority of the headcount reductions from the Company’s research group. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$208.00M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$977.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+47.7%
Year over year · more shares
Price change (1Y)
+174.1%
Trailing year
Short interest
28.5%
Latest settlement · 9.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −3%
below
RSI (14) 48
neutral
MACD trend Negative
52-week position 59%
mid-range
Momentum
relative strength
Strong
1-month return −19%
trailing
6-month return −2%
trailing
YTD return +156%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $23 › 200d $23 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
28.47% of shares out · ▲ +7.7% MoM · 9.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
259 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
Revenue growth +48%
Y/Y
EPS growth +27%
Y/Y
Free cash flow $-139.9M
Quant / Vol
risk profile
Very High
Volatility 101%
annualized · 1-yr
Max drawdown −37%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−3% Neutral
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
59% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $23 › 200d $23 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
28.47% of shares out · ▲ +7.7% MoM · 9.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
259 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $23 · 59% Range high $33
vs 200-day avg -2% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash position $977.5M As of September 30, 2026 —
TNG961 direct program expenses $59K the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TNGX
Tango Therapeutics, Inc.
this stock
$3.85B +156.3% +48.3% — 28.5%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
259
% held
126.0%
Net QoQ
-303.9K sh
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
251
View
Short & Settlement
Short Interest Rising
Shares short
48.2M
Days to cover
9.7d
Change
+3.5M sh
View
Short Volume
Short vol %
55%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
482.0K
Value
$10.9M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
39.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$62.4M
Net income (FY)
$-101.6M
EPS diluted
$-0.87
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
25

Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.

View
Proposed Sales
Value
$183.5K
Shares
7.6K
Filed
Nov 17, 2026
View
Exempt Offerings
Offering
$15.0M
Filed
Oct 28, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Tango Therapeutics Reports Third…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
TNGX -8.6% -18.7% -1.7% 0.0% +156.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -3.2% -12.4% +3.9% +5.2% +151.3%
Key facts CIK 1819133 CUSIP 87583X109 13F (30d) 267 filings 250 filers Visit website Investor relations